{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:01:51Z","timestamp":1767772911679,"version":"3.41.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Evaluate differences between blood transfusion and complication rates among fragility hip fracture patients treated with locally injected (Local) versus intravenous (IV) tranexamic acid (TXA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">\n                                    Design\n                                 <\/jats:italic>\n                                 <jats:bold>\n                                    :\n                                 <\/jats:bold> Retrospective comparative cohort.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Tertiary referral orthopaedic specialty hospital; Level I trauma center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient Selection Criteria:<\/jats:title>\n            <jats:p>Patients aged 50 years and over who underwent surgical treatment for a proximal femur fragility fracture (Orthopedic Trauma Association\/Arbeitsgemeinschaft f\u00fcr Osteosynthesefragen 31A and 31B). Between March 2018 and April 2022 with or without the use of local TXA during wound closure or IV TXA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcome Measures and Comparisons:<\/jats:title>\n            <jats:p>Postoperative blood transfusion, venous thromboembolism, surgical site infections, and 30-day readmissions compared between those who received IV TXA, Local TXA, and controls that did not receive any TXA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Seven hundred forty-six patients (258 received IV TXA, 252 received Local TXA, and 236 controls that did not receive any TXA) were studied. Both Local and IV TXA groups received fewer blood transfusion versus controls. IV TXA was associated with a transfusion rate reduction of 12% compared with Local TXA (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Regression analysis indicated that IV TXA reduced the odds of a postoperative blood transfusion by 48% compared with Local TXA (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.017). There were no differences in complication rates among the groups; however, patients receiving IV TXA had a significantly lower 30-day readmission rate (5%) than the control (13.9%) or Local (13.8%) TXA groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>IV TXA significantly reduced the risk of postoperative transfusion compared with controls and patients receiving Local TXA. There was no increased risk of complications, and a lower 30-day readmission was observed for the IV TXA group. IV TXA seems to be a safe and effective way to reduce postoperative blood transfusion in patients with fragility hip fractures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LEVEL OF EVIDENCE:<\/jats:title>\n            <jats:p>Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bot.0000000000002737","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T05:03:42Z","timestamp":1702616622000},"page":"e79-e84","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Intravenous Versus Locally Injected Tranexamic Acid in a Fragility Hip Fracture Population: A Retrospective Review"],"prefix":"10.1097","volume":"38","author":[{"given":"Stephen L.","family":"Davis","sequence":"first","affiliation":[{"name":"Bone and Joint Institute at Hartford Hospital, Hartford Healthcare, Hartford, CT; and"},{"name":"Orthopedic Associates of Hartford, Hartford, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Solomito","sequence":"additional","affiliation":[{"name":"Bone and Joint Institute at Hartford Hospital, Hartford Healthcare, Hartford, CT; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Bone and Joint Institute at Hartford Hospital, Hartford Healthcare, Hartford, CT; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250614","first-page":"1","article-title":"The efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis","volume":"19","author":"Qi","year":"2019","journal-title":"J Orthop Transl"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/os.12511","article-title":"Efficacy and safety of tranexamic acid in intertrochanteric fractures: a single-blind randomized controlled trial","volume":"11","author":"Zhou","year":"2019","journal-title":"Orthop Surg"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"e010676","DOI":"10.1136\/bmjopen-2015-010676","article-title":"Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients","volume":"6","author":"Gausden","year":"2016","journal-title":"BMJ Open"},{"key":"R4-20250614","first-page":"945","article-title":"Hip fracture: diagnosis, treatment, and secondary prevention","volume":"89","author":"Leblanc","year":"2014","journal-title":"Am Fam Physician"},{"key":"R5-20250614","first-page":"120","article-title":"Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial","volume":"25","author":"Chen","year":"2019","journal-title":"Hong Kong Med J"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/bcp.13079","article-title":"A systematic review of tranexamic acid in hip fracture surgery","volume":"82","author":"Farrow","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.injury.2010.02.015","article-title":"The hidden blood loss after hip fracture","volume":"42","author":"Smith","year":"2011","journal-title":"Injury"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13018-017-0625-9","article-title":"Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial","volume":"12","author":"Lei","year":"2017","journal-title":"J Orthop Surg Res"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0033-3506(05)80614-6","article-title":"What is the true mortality of hip fractures?","volume":"105","author":"Parker","year":"1991","journal-title":"Public Health"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/BOT.0000000000000919","article-title":"Efficacy and safety of tranexamic acid in orthopaedic fracture surgery: a meta-analysis and systematic literature review","volume":"31","author":"Amer","year":"2017","journal-title":"J Orthop Trauma"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2008-10-167643","article-title":"Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention","volume":"113","author":"Vamvakas","year":"2009","journal-title":"Blood"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.arth.2016.08.026","article-title":"Allogeneic blood transfusion is a significant risk factor for surgical-site infection following total hip and knee arthroplasty: a meta-analysis","volume":"32","author":"Kim","year":"2017","journal-title":"J Arthroplasty"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.arth.2012.04.024","article-title":"Tranexamic acid for reduction of blood loss during total hip arthroplasty","volume":"27","author":"Imai","year":"2012","journal-title":"J Arthroplasty"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.arth.2014.08.022","article-title":"Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty","volume":"30","author":"Duncan","year":"2015","journal-title":"J Arthroplasty"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.arth.2014.03.011","article-title":"Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study","volume":"29","author":"Patel","year":"2014","journal-title":"J Arthroplasty"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.arth.2013.06.011","article-title":"Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty","volume":"28","author":"Konig","year":"2013","journal-title":"J Arthroplasty"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.arth.2016.07.004","article-title":"Intravenous vs intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind trial","volume":"32","author":"Goyal","year":"2017","journal-title":"J Arthroplasty"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13018-017-0520-4","article-title":"Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials","volume":"12","author":"Li","year":"2017","journal-title":"J Orthop Surg Res"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1302\/0301-620X.103B3.BJJ-2021-0172","article-title":"Infographic: single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial","volume":"103-B","author":"Nikolaou","year":"2021","journal-title":"Bone Joint J"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/BOT.0000000000002241","article-title":"Efficacy and safety of locally injected tranexamic acid in hip fracture patients: a retrospective review","volume":"36","author":"Witmer","year":"2022","journal-title":"J Orthop Trauma"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.thromres.2017.03.009","article-title":"Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: an updated meta-analysis","volume":"153","author":"Xie","year":"2017","journal-title":"Thrombosis Res"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2106\/JBJS.15.01010","article-title":"The Michican experience with saftey and effectiveness of tranexamic acid use in hip and knee arthroplasty","volume":"98","author":"Hallstrom","year":"2016","journal-title":"JBJS"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.arth.2013.10.005","article-title":"Topical administration of tranexamic acid in primary total hip and total knee arthroplasty","volume":"29","author":"Martin","year":"2014","journal-title":"J Arthroplasty"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"e26565","DOI":"10.1097\/MD.0000000000026565","article-title":"Evaluation of efficacy and safety of systemic and topical intra-articular administration of tranexamic acid in primary unilateral total hip arthroplasty","volume":"100","author":"Juraj","year":"2021","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Orthopaedic Trauma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOT.0000000000002737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T18:02:36Z","timestamp":1749924156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOT.0000000000002737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bot.0000000000002737","relation":{},"ISSN":["0890-5339"],"issn-type":[{"type":"print","value":"0890-5339"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"2023-11-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}